Biogen Is Maintained at Outperform by BMO Capital
Biogen Analyst Ratings
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $230
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $225
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $225
Maintaining Hold on Biogen Amid Modest Growth and Cautious Outlook
Morgan Stanley Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $285
Raymond James Downgrades Biogen(BIIB.US) to Hold Rating
Biogen Analyst Ratings
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and Traws Pharma (TRAW)
J.P. Morgan Maintains Biogen(BIIB.US) With Hold Rating, Announces Target Price $220
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Biogen (BIIB)
Barclays Initiates Biogen(BIIB.US) With Hold Rating, Announces Target Price $190
RBC Cuts Price Target on Biogen to $269 From $292, Keeps Outperform Rating
Biogen Is Maintained at Neutral by UBS
Biogen Analyst Ratings
UBS Initiates Biogen(BIIB.US) With Hold Rating, Announces Target Price $202
Mizuho Securities Maintains Biogen(BIIB.US) With Buy Rating
Baird Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
BMO Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $260